FILE:SYK/SYK-8K-20030715160149.txt.gz
EVENTS:	Financial statements and exhibits	Regulation FD Disclosure
TEXT:
ITEM: Financial statements and exhibits
ITEM: Regulation FD Disclosure
 
 
 
 
 
Stryker Corporation issued a press release on July 15, 2003 announcing its second quarter and first half 2003 operating results.  A copy of this press release is attached hereto as Exhibit 99.1.  This information is being provided pursuant to Item 12 (Results of Operations and Financial Condition).
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 

Exhibit 99.1
        Kalamazoo, Michigan -- July 15, 2003 -- Stryker Corporation (NYSE:SYK) reported today that net sales were $891.7 million for the second quarter of 2003, representing a 22% increase over net sales of $733.9 million in the second quarter of 2002 and $1,738.6 million for the first half of 2003, representing a 21% increase over net sales of $1,436.8 million for the first half of 2002.  Excluding the impact of foreign currency, net sales increased 16% for both the second quarter and the first half.
        Net earnings for the second quarter of 2003 were $107.5 million, representing a 25% increase over net earnings of $85.9 million in the second quarter of 2002.  Diluted net earnings per share for the second quarter increased 26% to $.53 compared to $.42 in the second quarter of 2002.  For the first half of 2003, net earnings were $211.6 million, representing a 27% increase over net earnings of $167.0 million in 2002.  Diluted net earnings per share increased 27% for the first half of 2003 to $1.04 compared to diluted net earnings per share of $.82 in the first half of 2002.  
        Domestic sales were $567.2 million for the second quarter and $1,113.4 million for the first half of 2003, representing increases of 19% and 18%, respectively, as a result of strong shipments of Orthopaedic Implants and MedSurg Equipment and higher revenue from Physical Therapy Services.
        International sales were $324.5 million for the second quarter and $625.2 million for the first half of 2003, representing increases of 27% in both periods, as a result of higher shipments of Orthopaedic Implants and MedSurg Equipment.  The impact of foreign currency comparisons to the dollar value of international sales was favorable by $39.3 million in the second quarter and by $76.0 million for the first half.  Excluding the impact of foreign currency, international sales increased 11% in both the second quarter and for the first half.
        Worldwide sales of Orthopaedic Implants were $522.2 million for the second quarter and $1,013.0 million for the first half of 2003, representing increases of 26% and 25%, respectively, based on higher shipments of reconstructive (hip, knee and shoulder), trauma and spinal implants.  Excluding the impact of foreign currency, sales of Orthopaedic Implants increased 19% in the second quarter and 18% for the first half.
        Worldwide sales of MedSurg Equipment were $312.9 million for the second quarter and $617.0 million for the first half of 2003, representing increases of 17% in both periods based on higher shipments of powered surgical instruments, endoscopic systems, hospital beds and stretchers and craniomaxillofacial implants.  Excluding the impact of foreign currency, sales of MedSurg Equipment increased 13% in the second quarter and 14% for the first half.
        Physical Therapy Services revenues were $56.6 million for the second quarter and $108.6 million for the first half of 2003, representing increases of 10% and 8%, respectively, as a result of new physical therapy centers and higher revenues from existing centers.
 
        The Company's effective income tax rate for the second quarter and first half of 2003 was reduced to 31.0% as compared to a 33.0% effective income tax rate for the second quarter and first half of 2002 and an effective annual income tax rate of 31.8% for the year ended December 31, 2002.  The income tax rate reduction results primarily from increased manufacturing in lower tax jurisdictions.
        As previously announced, the Company will conduct a conference call for financial analysts at 5:00 p.m. Eastern Time, today.  To hear the conference call, dial 800/894-4892.  A simultaneous webcast of the call may be accessed via the Company's website at .  The call will be archived on this website for 90 days.   A recording of the call may also be accessed from 7:00 p.m., Eastern Time, today until 7:00 p.m. on  July 17, 2003 by calling 800/633-8284 (domestic) or 402/977-9140 (international) and entering the reservation number 21153559.
www.strykercorp.com
 
        Stryker Corporation develops, manufactures and markets specialty surgical and medical products worldwide, including reconstructive implants, spinal, trauma and craniomaxillofacial systems, the bone growth factor osteogenic protein-1, powered surgical instruments, endoscopic and surgical navigation systems and patient care and handling equipment and provides outpatient physical therapy services in the United States. 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dean H. Bergy, Vice President, Chief Financial Officer and Secretary, 269/385-2600
Contact Information:


